Search
Esperion Therapeutics Inc
ESPRAdd to Watchlist
3.180USD
0.0000.00%
Close 07-10 16:00（ET）Quotes delayed by 15 min
819.46MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-10The current earnings forecast score of Esperion Therapeutics Inc is 6.00, ranking 132 out of 157 in the Pharmaceuticals industry. The average price target is 4.50, with a high of 16.00 and a low of 1.72.
Analyst Rating
Based on
6
analysts
Hold
Current Rating
3.160
Target Price
-0.63%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Esperion Therapeutics Inc
ESPR
6
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
Pfizer Inc
PFE
32
AbbVie Inc
ABBV
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Esperion Therapeutics Inc's expected revenue for the next quarter?
Esperion Therapeutics Inc's expected revenue is 90.95M.
What is Esperion Therapeutics Inc's price target?
Analysts forecast that Esperion Therapeutics Inc's price target is USD 4.50, with the highest forecast at USD 16.00 and the lowest forecast at USD 1.72.
How have Esperion Therapeutics IncESPR's recent earnings per share performed?
The market expectation was USD -0.10, while Esperion Therapeutics IncESPR's earnings per share (EPS) for the previous quarter was USD 0.26. EPS for the next quarter is expected at USD -0.01.
What is the analyst rating for Esperion Therapeutics Inc?
Based on the ratings of Esperion Therapeutics Inc's stock from 6 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.